- within Food, Drugs, Healthcare and Life Sciences topic(s)
- within Criminal Law, Insolvency/Bankruptcy/Re-Structuring and Consumer Protection topic(s)
- with readers working within the Law Firm industries
The regulatory landscape in July 2026 was marked by significant developments across pharmaceuticals, medical devices, digital health, medical education, and healthcare regulation. Key developments included the draft National Pharmacy Commission Bill, CDSCO consultations on pharmaceutical brand naming, guidance on Medical Device Software, and several enforcement and compliance initiatives affecting the life sciences sector.
This Newsletter aims to highlight key regulatory and policy developments relevant to pharmaceutical, biotechnology, medical devices, and healthcare sector stakeholders operating in India.
Key Takeaways
- The MoHFW released the draft National Pharmacy Commission Bill, 2026, proposing the repeal of the Pharmacy Act, 1948, and the introduction of a national pharmacist register.
- The 69th DCC recommended tighter scrutiny of unapproved drugs/FDCs through a comprehensive approval database, mandatory registration of blood centres on e-RaktKosh, regulatory oversight of pharmaceutical packaging material suppliers, and public disclosure of enforcement actions by States.
- CDSCO initiated consultations on restricting look-alike/sound-alike (LASA) pharmaceutical brand name extensions and suffixes, signaling potential stricter nomenclature guidelines under the Drugs Rules, 1945.
- CDSCO directed manufacturers to incorporate additional adverse drug reactions into prescribing information for specified formulations, including Aceclofenac, Ibuprofen, Tranexamic Acid, Cotrimoxazole, Metronidazole, Tetracycline, Vancomycin, Azithromycin, Piperacillin + Tazobactam and Oral Itraconazole.
- The MoHFW issued the Drugs (Tenth Amendment) Rules, 2026, bringing oral formulations containing more than 12% alcohol v/v in packs exceeding 30 ml under Schedule H1 prescription controls.
- CDSCO issued final Guidance on Medical Device Software (MDSW), providing regulatory clarity on classification, licensing and other requirements for software qualifying as a medical device under the Medical Devices Rules, 2017.
- CDSCO issued a regulatory alert on cancellation of Ethics Committee registration certificates under the NDCT Rules, 2019, and directed enhanced surveillance on imported cosmetics sold without valid Import Registration Certificates under the Cosmetics Rules, 2020.
- NMC mandated ABDM-HMIS integration for medical colleges, proposed draft amendments to medical college regulations, operationalized online appeal portals for RMPs and institutions, and issued competency-based PwBD assessment guidelines for MBBS admissions.
- NPPA notified retail prices of 39 new drug formulations under DPCO, 2013, and issued clarifications on Form-IA filing under the DPCO Amendment 2026, simplifying market entry for subsequent manufacturers.
- Judicial pronouncements from the Delhi, Allahabad, and Madhya Pradesh High Courts reinforce strict standards for pharmaceutical trademarks, medical qualifications, and reproductive rights.
Pharmaceuticals & Drug Regulation
MoHFW Releases Draft National Pharmacy Commission Bill, 2026
On July 1, 2026, the Ministry of Health and Family Welfare (MoHFW) released the draft National Pharmacy Commission Bill, 2026, (second version) for public consultation. The Bill seeks to repeal the Pharmacy Act, 1948, and replace the existing Pharmacy Council of India (PCI) with a National Pharmacy Commission. This proposed legislation aims to decentralize the regulatory framework, introduce a national register for pharmacists, and implement a standardized exit exam to ensure professional competency across all states.
Why this matters
If enacted, the Bill would significantly overhaul how India regulates pharmacy education and practice, replacing a nearly 80-year-old law with a unified commission-led system governing education, licensing, registration, ethics, and institutional oversight.
Principal Issues Considered at the 69th DCC Meeting
The 69th Drugs Consultative Committee (DCC) meeting focused on curbing unapproved drugs/FDCs through a comprehensive approval database and stronger regulatory action, including possible amendments to require online submissions through ONDLS. It also addressed blood safety, recommending statutory provisions for mandatory registration of blood centres on e-RaktKosh and further deliberation on EQAS and biometric authentication of donors. A further key issue was supply-chain integrity, particularly whether manufacturers/suppliers of printed pharmaceutical packaging materials should be brought under a formal regulatory framework to prevent diversion for spurious or counterfeit drugs. The DCC additionally emphasized greater enforcement transparency, directing States to publicly disclose licence suspensions/cancellations, stop orders and recall alerts, and to share monthly compliance/ Not of Standard Quality data with CDSCO.
Why this matters
The DCC’s recommendations indicate tighter scrutiny, stronger digital and enforcement mechanisms, and may inform future regulatory or administrative measures that could materially affect licensing, compliance, and market access for drug and blood-sector stakeholders.
CDSCO Consults on Pharmaceutical Brand Name Extensions and Suffixes
On July 6, 2026, the CDSCO (Central Drugs Standard Control Organisation) released a public notice inviting stakeholder comments on the practice of using identical root brand names with different suffixes for drug formulations containing different Active Pharmaceutical Ingredients (APIs). This consultation follows recommendations from the 67th Drugs Consultative Committee (DCC), which noted that such branding could mislead consumers and healthcare professionals, particularly in clinical settings involving handwritten prescriptions or verbal instructions. The regulator is evaluating whether existing provisions under the Drugs Rules, 1945, are sufficient to address look-alike/sound-alike (LASA) risks or if stricter nomenclature guidelines are required.
Why this matters
The consultation indicates increased regulatory scrutiny of pharmaceutical brand extensions from a patient-safety perspective and may result in tighter requirements governing the use of common root brand names across formulations.
CDSCO Safety Labelling Updates for Drug Formulations (21st July 2026)
CDSCO directed that additional adverse drug reactions be incorporated into the prescribing information leaflets, package inserts, and promotional literature of specified formulations marketed in India. The affected products and ADRs are Aceclofenac and Ibuprofen for "Fixed Drug Eruption"; and Tranexamic Acid for "Back Pain". State/UT authorities have been asked to direct manufacturers under their jurisdiction to make these changes and report action taken back to CDSCO.
Why this matters
These directions trigger immediate regulatory compliance obligations for manufacturers to update product safety disclosures, with heightened scrutiny on labelling, promotional claims, and pharmacovigilance risk communication.
Aceclofenac (Link Here), Ibuprofen (Link Here), Tranexamic Acid (Link Here)
CDSCO Safety Labelling Updates for Drug Formulations (6th July 2026)
CDSCO directed that certain newly identified adverse drug reactions be incorporated into the prescribing information leaflets, package inserts and promotional literature of specified formulations marketed in India. The affected products and ADRs are Cotrimoxazole, Metronidazole, Tetracycline and Azithromycin for “Fixed Drug Eruption”; Vancomycin for “DRESS Syndrome”; Oral Itraconazole for “Symmetrical Drug Related-Intertriginous and Flexural Exanthema”, and Piperacillin + Tazobactam for “Blurred Vision”. State/UT authorities have been asked to direct manufacturers under their jurisdiction to make these changes and report action taken back to CDSCO.
Why this matters
These directions trigger immediate regulatory compliance obligations for manufacturers to update product safety disclosures, with heightened scrutiny on labelling, promotional claims, and pharmacovigilance risk communication.
Vancomycin (Link Here), Cotrimoxazole (Link Here), Tetracycline (Link Here)
Metronidazole (Link Here), Oral Itraconazole (Link Here), Piperacillin + Tazobactam (Link Here)
Azithromycin (Link Here)
Navi Mumbai Airport Notified as Authorized Port for Drug Imports
The Central Government, through a Gazette notification (Drugs (Ninth Amendment) Rules, 2026) on July 2, 2026, has notified Navi Mumbai International Airport as an authorized port for the import of drugs under the Drugs Rules, 1945. This designation adds the new airport to the list of authorized entry points, facilitating the direct arrival of pharmaceutical consignments and specialized medical equipment into the Mumbai Metropolitan Region.
Why this matters
The notification provides an additional authorized entry point for pharmaceutical imports into the Mumbai Metropolitan Region, which may facilitate import logistics, including for temperature-sensitive products.
MoHFW Tightens Controls on High-Alcohol Oral Formulations
The MoHFW issued the Drugs (Tenth Amendment) Rules, 2026 to amend the Drugs Rules, 1945 (Drugs Rules), which shall come into force six months after publication. The amendment makes two key changes: first, it modifies Schedule K to exclude from exemption all oral formulations containing more than 12% alcohol v/v (Ethyl Alcohol) packed and sold in packings or bottles of more than 30 milliliters; and second, it inserts the same category of formulations as Entry 52 in Schedule H1, thereby bringing them under prescription-only/restricted sale requirements.
Why this matters
Upon commencement, this amendment will bring high-alcohol oral formulations (>12% v/v in >30ml packs) under Schedule H1 prescription controls, effectively curbing their over-the-counter sale and potential misuse as surrogate alcohol.
Clarification regarding submission of applications under Rule 4 of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025
CDSCO has issued a clarification regarding the submission of applications for the compounding of offences under Rule 4 of the Drugs and Cosmetics (Compounding of Offences) Rules, 2025. Applications must be directed to the appropriate Compounding Authority that holds jurisdiction over the offence in question. In instances where a sample has been collected by a Drugs Inspector appointed by a State or Union Territory Government and the offence falls within the jurisdiction of the respective State or UT Drugs Licensing Authority, the application should be submitted to that authority. Conversely, if a Drugs Inspector from the CDSCO has taken the sample, then the application must be submitted to the Central Compounding Authority.
Why this matters
Applicants seeking compounding of offences often face uncertainty over which authority to approach, leading to misdirected applications, procedural rejections, and avoidable delays. This clarification removes that ambiguity by tying jurisdiction directly to the identity of the sampling authority.
Medical Devices
CDSCO Notifies Final Guidance Document on Medical Device Software (MDSW)
On July 21, 2026, the CDSCO, Medical Devices Division, issued the final Guidance Document on Medical Device Software (MDSW). The guidance establishes distinct market access pathways for medical devices and IVDs (In-Vitro Diagnostics) qualifying as MDSW, covering classification, clinical investigation requirements, licensing authorities, and post-market surveillance. It clarifies that embedded software/firmware integral to a hardware medical device does not require a separate licence, but standalone software sold separately does require licensing under MDR-2017.
Why this matters
The final guidance provides greater regulatory clarity for software qualifying as a medical device under the Medical Devices Rules, 2017, including on classification, licensing and applicable regulatory requirements.
Clinical Trials
CDSCO Issues Regulatory Alert on Cancellation of Ethics Committee Registration Certificates
On July 24, 2026, the CDSCO issued a Regulatory Alert regarding the cancellation of Registration Certificates of Ethics Committees under the New Drugs and Clinical Trials Rules, 2019. The alert notifies stakeholders that the registration certificates of certain Ethics Committees have been cancelled due to non-compliance with the requirements prescribed under the NDCT Rules, 2019. Ethics Committees are required to be registered with the CDSCO to review and approve clinical trials of new drugs and investigational medical devices.
Why this matters
The cancellation alert highlights CDSCO's enforcement of Ethics Committee compliance under the NDCT Rules, 2019. Sponsors should verify the registration status of Ethics Committees before relying on approvals for regulatory submissions.
ICMR Issues Draft Ethical Guidance for Non-Regulatory Clinical Trials
This draft guidance sets out the ethical framework for non-regulatory clinical trials (NRCTs) in India, i.e., interventional studies using approved or non-CDSCO-regulated health interventions for academic, scientific, or public health purposes rather than marketing approval. It requires prior scientific review and ethics committee approval, with ethics committees registered on the DHR NAITIK portal, and emphasizes risk-based review, informed consent, adverse event/ serious adverse effect reporting, medical management, and compensation for research-related injury where applicable. The guidance also covers monitoring, postgraduate thesis-related NRCTs, data management/document retention, Clinical Trial Registry-India registration, and the respective responsibilities of investigators and institutions to ensure ethical conduct and participant protection throughout the study lifecycle.
Why this matters
It provides a formal ethical compliance framework for investigator-led non-regulatory clinical trials in India, clarifying approval, consent, safety, monitoring, and institutional accountability requirements.
Cosmetics
CDSCO Directs Enhanced Vigilance on Unregistered Imported Cosmetics in Domestic Market
Through a circular dated July 22, 2026, the CDSCO, Cosmetics Division directed port officers and State Licensing Authorities to intensify surveillance on imported cosmetic products being sold in the domestic market without a valid Import Registration Certificate (RC) under the Cosmetics Rules, 2020. The circular notes that it has come to the regulator's notice that imported cosmetics are circulating in the domestic market without valid RCs, and directs authorities to ensure that imported cosmetics are not sold without the requisite registration.
Why this matters
The circular signals CDSCO's intent to crack down on imported cosmetics sold without valid registration. Importers, distributors, and retailers should verify that all imported products in their supply chains carry valid Import Registration Certificates to avoid enforcement action under the Drugs and Cosmetics Act, 1940.
AYUSH
NCISM Circular Affirms Legal Standing of Registered AYUSH Practitioners, Bars Use of Term 'Quack'
On July 29, 2026, the National Commission for Indian System of Medicine (NCISM) issued a circular clarifying that duly qualified and registered practitioners of the Indian System of Medicine, including graduates of Ayurveda (BAMS), Unani (BUMS), Siddha (BSMS), and Sowa-Rigpa (BSRMS), are legally recognised medical practitioners under the NCISM Act, 2020. The circular explicitly states that there is no legal basis for describing such registered practitioners as 'quacks' or 'bogus doctors' and seeks to prevent their public mischaracterisation while affirming their place in India's healthcare workforce.
Why this matters
The circular is significant for the AYUSH sector as it formally asserts the legal standing of registered practitioners against pejorative labelling, which has been a longstanding grievance. It may also influence pending and future litigation where the status of AYUSH practitioners is contested.
Medical Education & Professional Regulation
NMC Proposes Draft Amendments to Medical College Regulations
Through a Gazette notification dated July 8, 2026, the National Medical Commission (NMC) proposed further amendments to medical college regulations. The draft amendments address eligibility criteria for applications, mandatory corpus fund requirements, and rejection criteria for incomplete applications. The proposal follows the NMC's ongoing effort to strengthen the regulatory framework for medical education institutions across India.
Why this matters
The amendments tighten compliance requirements for medical colleges, including financial accountability through a mandatory corpus fund and stricter application scrutiny to prevent substandard institutions from operating.
NMC Operationalizes Online Appeal Portal for Registered Medical Practitioners
On July 23, 2026, the NMC operationalized the NMC Online Appeal Portal for filing of appeals by Registered Medical Practitioners (RMPs) under Section 30(3) and Section 30(4) of the National Medical Commission Act, 2019. The portal enables medical practitioners to file appeals electronically against decisions of the State Medical Councils, streamlining the grievance redressal process and reducing dependence on physical submissions.
Why this matters
The online appeal portal digitizes a previously paper-based process, improving transparency and accessibility for medical practitioners seeking redressal of registration and disciplinary matters.
NMC Office Memorandum Mandates ABDM-Compliant HMIS Integration for Medical Colleges
On July 17, 2026, the NMC issued an Office Memorandum directing all medical colleges and institutions to implement an Ayushman Bharat Digital Mission (ABDM)-compliant Health Management Information System (HMIS). The mandate requires integration with the ABDM-HMIS portal and completion of three specific milestones: M1 (ABHA integration), M2 (Health Record Linking), and M3 (Advanced data sharing).
Why this matters
The Office Memorandum effectively transforms digital health infrastructure compliance from a recommended best practice into a binding regulatory condition for medical colleges.
NMC Issues Competency-Based Assessment Guidelines for Persons with Benchmark Disabilities (PwBD) for MBBS Admissions
On July 27, 2026, the NMC issued guidelines establishing a "competency-based and function-oriented" framework for assessing Persons with Benchmark Disabilities (PwBD) for MBBS admissions. The guidelines shift eligibility determination away from rigid numerical disability percentages toward a candidate's actual ability to perform medical tasks with "reasonable accommodation" and assistive technology. Medical colleges are further encouraged to implement periodic faculty sensitization programs to eliminate attitudinal and physical barriers in the learning environment.
Why this matters
The guidelines mark a departure from percentage-based disability thresholds toward a functional competency model, potentially expanding access to medical education for PwBD candidates while placing new assessment and accommodation obligations on medical colleges.
NMC Launches Online Appeal Portal for Filing of Appeals by Medical Colleges/Institutions
The NMC has launched a dedicated Online Appeal Portal for medical colleges/institutions to file appeals against Medical Assessment and Rating Board (MARB), Under-Graduate Medical Education Board, and Post-Graduate Medical Education Board, decisions under the National Medical Commission Act, 2019, effective from the notice date. All appeals must now be filed exclusively through the portal; the earlier e-mail and physical filing modes stand discontinued with immediate effect.
Why this matters
The portal centralizes and digitizes the institutional appeal process, replacing prior e-mail and physical filing routes. Medical colleges should transition to the online platform immediately, as legacy filing modes are no longer accepted.
Mandatory Fresh Registration & Two-Factor Authentication for all Students on DIGI-PHARMed Portal
The Pharmacy Council of India (PCI) issued a circular which directs fresh registration of all students (D.Pharm, B.Pharm, M.Pharm) on the DIGI-PHARMed Portal to fix issues like duplicate/incomplete records and enable Aadhaar Enabled Biometric Attendance System (AEBAS). Students must complete Two-Factor Authentication (OTP) verification within 7 days, or their profiles will be deactivated; only freshly registered and verified profiles will be eligible for AEBAS onboarding. Institutions must complete student registration/processing within 30 days, verify educational documents, and update academic progression each year, as these records will also feed into future State Pharmacy Council registration.
Why this matters
It matters because students whose profiles aren't OTP-verified within 7 days will be deactivated and become ineligible for AEBAS attendance marking, directly risking their academic continuity and course validity.
Pricing Control
NPPA Fixes Retail Prices of 39 New Drug Formulations Under DPCO, 2013
NPPA notified retail prices of 39 new drug formulations under Drugs (Pricing Control) Order, 2013 (DPCO) as part of its ongoing price fixation exercise. The notification follows the amended DPCO framework, which allows other existing manufacturers launching the same new drug within 12 months of retail price fixation to do so without prior price approval, subject to filing a Form-IA intimation within one month of launch.
Why this matters
The notification continues NPPA's routine price fixation function but under the new amended DPCO framework, which simplifies the process for subsequent manufacturers entering the market for the same drug.
Clarifications on Form-IA Filing Under DPCO Amendment 2026
The National Pharmaceutical Pricing Authority (NPPA) has issued clarifications on the filing of Form-IA under the Drugs (Prices Control) Amendment Order, 2026 (DPCO Amendment 2026), effective July 1, 2026. Under the revised framework, an existing manufacturer of National List of Essential Medicines drug launching a new drug must seek prior price approval via Form-I, while any other manufacturer launching the same new drug may do so at a price not exceeding the NPPA-notified retail price, within twelve months of such fixation. Such manufacturers must submit Form-IA within one month of launch through the IPDMS 2.0 portal, along with all supporting documents listed in Annexure-I, and are cautioned against false or incorrect claims, which may attract penal proceedings under DPCO.
Why this matters
It operationalizes the 13th Amendment to DPCO, directly impacting how pharmaceutical manufacturers price and launch new drugs in India under NPPA oversight.
Accreditation
NABH Issues Public Notices on Digital Health Standards and AYUSH Entry Level Standards
The National Accreditation Board for Hospitals and Healthcare Providers (NABH) issued multiple notifications in July 2026: a public notice for Digital Health Standards (HIS EMR 2nd Edition) on July 22, 2026; public notices inviting comments on draft 2nd Edition NABH Entry Level Standards for AYUSH Centres on July 22, 2026, and for AYUSH Hospitals on July 19, 2026; and a notification for Assessor Logistics for NABH Accreditation, Certification and Empanelment Program on July 28, 2026.
Why this matters
The Digital Health Standards update aligns hospital accreditation with India's evolving digital health infrastructure, while the draft AYUSH standards update the accreditation framework applicable to AYUSH centres and hospitals.
July 22 Link Here, July 22 Link Here, July 19 Link Here & July 28 Link Here
Pharmacy Council of India (PCI) approves NABH-accredited hospitals for D.Pharm practical training
The PCI approved practical training placements for Diploma in Pharmacy students at NABH-accredited hospitals, alongside a final reminder to pharmacy institutions on mandatory implementation of the Aadhaar Enabled Biometric Attendance System (AEBAS) ahead of academic-session approval for 2026–27.
Why this matters
Pharmacy institutions should review their AEBAS compliance and practical-training arrangements for the 2026–27 academic session in light of the PCI requirements.
Government Initiatives
DHR Issues Draft National Health Research Policy 2026
The Department of Health Research (DHR) released the Draft National Health Research Policy, 2026 for public consultation, with comments invited until July 27, 2026. The draft seeks to establish a coordinated national architecture for India’s health research ecosystem, rather than a collection of isolated institutions and studies. The objective of this policy is to align research priorities with India’s healthcare needs through a new National Health Research Agenda along with other important elements of governance, infrastructure, workforce, funding, and collaboration with industries. The policy also emphasizes ethics, research integrity, and translating research into real policies, products, and clinical practice rather than just publications.
Why this matters
The draft policy, if adopted, could materially influence national research priorities, funding, governance, industry collaboration and translation of health research into products and clinical practice.
Food Laws (Select Regulatory Developments)
FSSAI Notifies Gazette Notification of NABL Accredited Laboratories Under Section 43(1) of FSS Act
On July 17, 2026, FSSAI notified a Gazette notification dated July 13, 2026, regarding NABL Accredited Laboratories under Section 43(1) of the Food Safety and Standards Act, 2006. The notification recognizes a revised list of laboratories authorized to conduct food testing and analysis for regulatory and compliance purposes under the Food Safety and Standards Act, 2006 (FSS Act).
Why this matters
The notification of NABL-accredited laboratories under Section 43(1) of the FSS Act maintains the integrity of the food testing ecosystem, ensuring that only properly accredited laboratories are authorized to test food samples for regulatory compliance.
Intellectual Property (Life Sciences)
Intellectual Property Office of India Mandates e-KYC for IP Attorneys
On July 9, 2026, the Intellectual Property Office of India issued a Public Notice requiring all registered IP attorneys to complete prescribed e-KYC verification within one month (by August 9, 2026). The mandate applies to patent agents, trademark attorneys, and other IP practitioners registered with the Indian IP Office, and is part of the office's broader digital transformation initiative to strengthen authentication and reduce fraudulent filings.
Why this matters
Pharma and biotech companies engaging IP attorneys for patent prosecution and trademark matters should ensure their counsel completes e-KYC verification to avoid disruption in filing and prosecution timelines.
NMC Advisory Launches 'Medical Innovations Patent Mitra' Initiative for Government-Funded Patent Support
On July 1, 2026, the NMC, in coordination with the Indian Council of Medical Research (ICMR), issued an advisory launching the 'Medical Innovations Patent Mitra' initiative. The program aims to fortify India's biomedical innovation ecosystem by offering end-to-end support for patent protection and technology transfer for healthcare research emerging from medical institutions. Critically, the initiative provides fully government-funded support for patent filing and technology transfer, enabling researchers within medical colleges to translate lab-scale research into commercial healthcare products without incurring significant administrative or legal overheads.
Why this matters
The initiative gives medical researchers and institutions free, government-backed support to patent and commercialize their healthcare innovations, turning research into protected IP and real-world medical products.
Key Judicial Developments
Sun Pharmaceutical Industries Ltd. v. Finecure Pharmaceuticals Ltd. (Delhi High Court, July 2026)
Sun Pharma appealed a single judge's refusal to injunct Finecure from selling 'Pantopacid', alleged to be deceptively similar to Sun Pharma's 'Pantocid'. The Division Bench restrained Finecure from selling 'Pantopacid', holding it deceptively similar to Sun Pharma's 'Pantocid'. Applying the Pianotist test and the Supreme Court's standard in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., the Court held that even shared prefixes may justify an injunction in the pharmaceutical sector due to patient safety concerns. Finecure's defense that 'Panto' derives from the INN 'Pantoprazole' (and is therefore publici juris) was rejected, as the potential for a patient to be dispensed the wrong brand constitutes infringement regardless of whether both products contain the same molecule. The Court allowed four months for transition.
Why this matters
The ruling reinforces Indian courts' strict approach to pharmaceutical trademarks, clarifying that reliance on an INN-derived prefix is insufficient if the overall mark creates a similar phonetic or visual impression.
Santosh Kumar Sharma v. State of U.P. (2026:AHC:138560-DB)
The Allahabad High Court held that an electrohomeopathy qualification does not entitle a person to practise allopathic medicine. Rejecting the petitioner's claim, the Division Bench ruled that practising modern medicine without a recognized qualification amounts to "quackery" and described such practitioners as mere "pretenders of medical knowledge." The Court emphasized that medical practice is a highly regulated profession and that permitting unqualified individuals to treat patients would pose serious risks to public health. It further clarified that Article 19(1)(g) of the Constitution does not protect the practice of a branch of medicine for which a person lacks the requisite qualifications, and that restrictions on medical practice constitute a valid exercise of the State's regulatory powers.
Why this matters
This ruling reinforces that alternative-medicine qualifications (like electrohomeopathy) cannot be used as a backdoor to practise allopathic medicine, strengthening legal safeguards against quackery and protecting patients from unqualified medical treatment.
Prosecutrix X v. The State of Madhya Pradesh and Others (2026: MPHC-JBP:48177& 2026:MPHC-JBP:51529)
The Madhya Pradesh High Court permitted the termination of a 10-week pregnancy of a 17-year-old rape survivor after a Medical Board confirmed that the procedure was medically safe and informed consent was obtained from the survivor and her mother. While granting relief, the Court observed that the matter should not have required judicial intervention, noting that Section 3 of the Medical Termination of Pregnancy Act, 1971 already empowers registered medical practitioners to approve terminations within the applicable statutory limits. Relying on the Supreme Court's decision in A v. State of Maharashtra (2024), the Court emphasized reproductive autonomy and cautioned healthcare authorities against routinely referring eligible cases to courts. It also directed the concerned authorities to ensure timely access to lawful abortion services and preserve medical evidence necessary for the related criminal proceedings.
Why this matters
The orders reaffirm that minors and survivors of rape are not required to seek judicial intervention for legal, time-sensitive abortions that are already permitted under the MTP Act. Furthermore, it urges healthcare authorities to refrain from transferring this responsibility to the judiciary, thereby facilitating a reduction in delays associated with urgent reproductive healthcare services.
Editor's Insight
The July 2026 developments reveal a multi-track regulatory strategy across India's life sciences and healthcare sector. Digital health infrastructure continues to mature, with the NMC mandating ABDM-compliant HMIS integration for medical colleges. CDSCO's final MDSW guidance, enforcement actions on imported cosmetics and Ethics Committee registrations, and consultations on LASA pharmaceutical branding demonstrate a sharpening focus on regulatory clarity and patient safety. Medical education reform is underway, with the NMC proposing amendments and introducing competency-based PwBD assessment guidelines. The NPPA's retail price fixation under the amended DPCO framework signals a calibrated approach to pricing.
Companies operating in the sector should closely monitor these developments, as they may affect regulatory strategy, compliance, and product lifecycle management in India.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
